CTLA4 and small cell lung carcinoma: Increasing evidence shows that blocking immune checkpoints, such as programmed death 1 (PD-1)/PD-L1 or cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), has a certain antitumor effect on patients with ES-SCLC [5, 6, 29].